Dirk-Jan van Beek1, Sjoerd Nell1, Wessel M C M Vorselaars1, Bert A Bonsing2, Casper H J van Eijck3, Harry van Goor4, Elisabeth J Nieveen van Dijkum5, Cornelis H C Dejong6,7, Gerlof D Valk8, Inne H M Borel Rinkes1, Menno R Vriens9. 1. Department of Endocrine Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. 2. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. 3. Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands. 4. Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands. 5. Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC Academic Medical Center, Amsterdam, The Netherlands. 6. Department of Surgery, Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands. 7. Department of Surgery, Universitätsklinikum Aachen, Aachen, Germany. 8. Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. 9. Department of Endocrine Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. mvriens@umcutrecht.nl.
Abstract
BACKGROUND: Little is known about complications after major duodenopancreatic surgery for duodenopancreatic neuroendocrine tumors (dpNETs) in multiple endocrine neoplasia type 1 (MEN1). Therefore, the incidence and severity of complications after major surgery for MEN1-related dpNETs were assessed. METHODS: Patients were selected from the population-based Dutch MEN1 database if they had undergone a Whipple procedure or total pancreatectomy from 2003 to 2017. Complications were graded according to the Clavien-Dindo classification (grade III or higher complications were considered a severe complication) and definitions from the International Study Group of Pancreatic Surgery. The Cumulative Complication Index (CCI®) was calculated as the sum of all complications weighted for their severity. Univariable logistic regression was performed to assess potential associations between predictor candidates and a severe complication. RESULTS: Twenty-seven patients (median age 43 years) underwent a major duodenopancreatic resection, including 14 Whipple procedures and 13 total pancreatectomies. Morbidity and mortality were 100% (27/27) and 4% (1/27), respectively. A severe complication occurred in 17/27 (63%) patients. The median CCI® was 47.8 [range 8.7-100]. Grade B/C pancreatic fistulas, delayed gastric emptying, bile leakage, hemorrhage, and chyle leakage occurred in 7/14 (50%), 10/27 (37%), 1/27 (4%), 7/27 (26%), 3/27 (11%) patients, respectively. Patients with a severe complication had longer operative time and higher blood loss. After Whipple, new-onset endocrine and exocrine insufficiency occurred in 1/13 and 9/14 patients, respectively. CONCLUSIONS: Major duodenopancreatic surgery in MEN1 is associated with a very high risk of severe complications and cumulative burden of complications and should therefore be reserved for a select subgroup of patients with MEN1-related dpNETs.
BACKGROUND: Little is known about complications after major duodenopancreatic surgery for duodenopancreatic neuroendocrine tumors (dpNETs) in multiple endocrine neoplasia type 1 (MEN1). Therefore, the incidence and severity of complications after major surgery for MEN1-related dpNETs were assessed. METHODS:Patients were selected from the population-based Dutch MEN1 database if they had undergone a Whipple procedure or total pancreatectomy from 2003 to 2017. Complications were graded according to the Clavien-Dindo classification (grade III or higher complications were considered a severe complication) and definitions from the International Study Group of Pancreatic Surgery. The Cumulative Complication Index (CCI®) was calculated as the sum of all complications weighted for their severity. Univariable logistic regression was performed to assess potential associations between predictor candidates and a severe complication. RESULTS: Twenty-seven patients (median age 43 years) underwent a major duodenopancreatic resection, including 14 Whipple procedures and 13 total pancreatectomies. Morbidity and mortality were 100% (27/27) and 4% (1/27), respectively. A severe complication occurred in 17/27 (63%) patients. The median CCI® was 47.8 [range 8.7-100]. Grade B/C pancreatic fistulas, delayed gastric emptying, bile leakage, hemorrhage, and chyle leakage occurred in 7/14 (50%), 10/27 (37%), 1/27 (4%), 7/27 (26%), 3/27 (11%) patients, respectively. Patients with a severe complication had longer operative time and higher blood loss. After Whipple, new-onset endocrine and exocrine insufficiency occurred in 1/13 and 9/14 patients, respectively. CONCLUSIONS: Major duodenopancreatic surgery in MEN1 is associated with a very high risk of severe complications and cumulative burden of complications and should therefore be reserved for a select subgroup of patients with MEN1-related dpNETs.
Authors: Rajesh V Thakker; Paul J Newey; Gerard V Walls; John Bilezikian; Henning Dralle; Peter R Ebeling; Shlomo Melmed; Akihiro Sakurai; Francesco Tonelli; Maria Luisa Brandi Journal: J Clin Endocrinol Metab Date: 2012-06-20 Impact factor: 5.958
Authors: Frederic Triponez; David Dosseh; Pierre Goudet; Patrick Cougard; Catherine Bauters; Arnaud Murat; Guillaume Cadiot; Patricia Niccoli-Sire; Jean-Alain Chayvialle; Alain Calender; Charles A G Proye Journal: Ann Surg Date: 2006-02 Impact factor: 12.969
Authors: C R C Pieterman; E B Conemans; K M A Dreijerink; J M de Laat; H Th M Timmers; M R Vriens; G D Valk Journal: Endocr Relat Cancer Date: 2014-05-06 Impact factor: 5.678
Authors: Sjoerd Nell; Inne H M Borel Rinkes; Helena M Verkooijen; Bert A Bonsing; Casper H van Eijck; Harry van Goor; Ruben H J de Kleine; Geert Kazemier; Elisabeth J Nieveen van Dijkum; Cornelis H C Dejong; Gerlof D Valk; Menno R Vriens Journal: Ann Surg Date: 2018-02 Impact factor: 12.969
Authors: Delphine Vezzosi; Catherine Cardot-Bauters; Nicolas Bouscaren; Maëlle Lebras; Mireille Bertholon-Grégoire; Patricia Niccoli; Nathalie Levy-Bohbot; Lionel Groussin; Philippe Bouchard; Antoine Tabarin; Philippe Chanson; Pierre Lecomte; Isabelle Guilhem; Nicolas Carrere; Eric Mirallié; François Pattou; Jean Louis Peix; Diane Goere; Françoise Borson-Chazot; Philippe Caron; Vanina Bongard; Bruno Carnaille; Pierre Goudet; Eric Baudin Journal: Eur J Endocrinol Date: 2014-12-23 Impact factor: 6.664
Authors: Carolina R C Pieterman; Joanne M de Laat; Jos W R Twisk; Rachel S van Leeuwaarde; Wouter W de Herder; Koen M A Dreijerink; Ad R M M Hermus; Olaf M Dekkers; Anouk N A van der Horst-Schrivers; Madeleine L Drent; Peter H Bisschop; Bastiaan Havekes; Inne H M Borel Rinkes; Menno R Vriens; Gerlof D Valk Journal: J Clin Endocrinol Metab Date: 2017-10-01 Impact factor: 5.958
Authors: Caroline L Lopez; Massimo Falconi; Jens Waldmann; Letizia Boninsegna; Volker Fendrich; Peter K Goretzki; Peter Langer; Peter H Kann; Stefano Partelli; Detlef K Bartsch Journal: Ann Surg Date: 2013-02 Impact factor: 12.969
Authors: Joanne M de Laat; Rob B van der Luijt; Carolina R C Pieterman; Maria P Oostveen; Ad R Hermus; Olaf M Dekkers; Wouter W de Herder; Anouk N van der Horst-Schrivers; Madeleine L Drent; Peter H Bisschop; Bas Havekes; Menno R Vriens; Gerlof D Valk Journal: BMC Med Date: 2016-11-15 Impact factor: 8.775
Authors: Weihua Kong; Max Benjamin Albers; Jerena Manoharan; Joachim Nils Goebel; Peter Herbert Kann; Moritz Jesinghaus; Detlef Klaus Bartsch Journal: Cancers (Basel) Date: 2022-04-11 Impact factor: 6.575
Authors: Dirk-Jan van Beek; Wessel M C M Vorselaars; Inne H M Borel Rinkes; Menno R Vriens Journal: Ann Surg Oncol Date: 2021-01-27 Impact factor: 5.344
Authors: Paul Viktor Ritschl; Hannah Kristin Miller; Karl Hillebrandt; Lea Timmermann; Matthäus Felsenstein; Christian Benzing; Brigitta Globke; Robert Öllinger; Wenzel Schöning; Moritz Schmelzle; Johann Pratschke; Thomas Malinka Journal: BMC Surg Date: 2022-03-04 Impact factor: 2.102